China's iKang Healthcare wants to go private in a management-led $1.1 billion offer that would see it delist from the U.S., making it among a handful of healthcare-related companies from the Middle Kingdom to pursue that strategy this year.
Chinese small-cap Lee's Pharm has signed CRO WuXi PharmaTech as its exclusive lab testing service to bolster the company's R&D program.
Chinese CRO WuXi Pharma posted more soaring revenue in the second quarter, but some costly investments and currency issues drove down the company's profits as it prepares to go private.
The word that China's top CRO WuXi PharmaTech would delist from the U.S. in a management-led $3.3 billion buyout opens up more paths to deal-making that may not reach the public as quickly.
WuXi PharmaTech, China's largest CRO, agreed to a $3.3 billion buyout deal that would take it off of Wall Street and into the hands of some private investors.
Chinese CRO WuXi PharmaTech, alongside partner TruTag Technologies, is developing tiny, edible bar codes designed to prevent drug counterfeiting, and the technology cleared its first hurdle.
Chinese CRO giant WuXi PharmaTech is looking to expand its investment portfolio, planning to debut a $250 million new fund that will back startups in the U.S. and China.
U.S. and China focused WuXi Healthcare Ventures Fund picked up $50 million from affiliated WuXi PharmaTech, the sprawling China-based biopharma CRO, according to documents filed with the U.S. Securities and Exchange Commission.
WuXi PharmaTech has been in expansion mode for its manufacturing, which of course, comes with financing pressures. To raise some cash for the expansion of its small-molecule manufacturing subsidiary, SynTheAll Pharmaceutical, WuXi intends to sell off 6% of the business in anticipation of raising $80 million.
WuXi PharmaTech sought and has been approved for an extension under U.S. Securities and Exchange Commission Rule 406 to keep confidential treatment of information excluded from Form F-1 filed on July 24, 2007, as amended, according to an order filed June 17.